Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION After an inspector asking for batch records you cannot produce this week, scientific-advice briefing book is what labeling negotiator can touch in a 505(b)(2) program relying on literature plus a bridging study. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this CMC and Development Pathways file.

DECISION Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. Scientific-advice briefing book reads as Proceed under protocol once an inspector asking for batch records you cannot produce this week is lined up to the same Pharma & Life Sciences population. 2. Scientific-advice briefing book is closer to Pause the pathway after an inspector asking for batch records you cannot produce this week; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in scientific-advice briefing book for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study. 4. Scientific-advice briefing book is missing the fact labeling negotiator needs after an inspector asking for batch records you cannot produce this week; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether scientific-advice briefing book supports the labeled claim labeling negotiator would keep. 3. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against an inspector asking for batch records you cannot produce this week and write the one fact that would move to drop a secondary for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in scientific-advice briefing book, then the action for labeling negotiator - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Owner and next date for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study - What changes to drop a secondary if an inspector asking for batch records you cannot produce this week is later withdrawn